2. Transdermal buprenorphine comparisons: Adverse events.

AE

TD Bup versus placebo

TD Bup versus controlled‐release Mor

TD Bup versus TD Fen

Böhme 2003

Poulain 2008

Sittl 2003

Sorge 2004

Pace 2007

Sarhan 2009

Placebo

35 μg/h Bup

52.5 μg/h Bup

70 μg/h Bup

Placebo

70 μg/h Bup

Placebo

35 μg/h Bup

52.5 μg/h Bup

70 μg/h Bup

Placebo

35 μg/h Bup

TD Bup

CR Mor

TD Bup

TD Fen

At least one AE

28/38

35/41

33/41

28/37

Asthenia

1/95

4/94

Central nervous system AE

20/38

23/41

19/41

20/37

Confusion

1/26

1/26

Constipation

2/95

9/94

2/26

10/26

Dizziness/confusion

0/95

0/94

Drowsiness/somnolence

3/26

2/26

Bup > Fen

Bup > Fen

Erythema

7/38

12/41

12/41

12/37

0/19a

0/26a

Exanthema

0/37a

0/35a

1/41a

0/38a

1/38

5/41

5/41

1/37

Fatigue

2/95

0/94

Gastrointestinal AE

26.30%

17.10%

36.60%

43.20%

Headache

3/26

4/26

Nausea

7/95

3/94

3/26

9/26

Pruritus

0/37a

0/35a

3/41a

1/38a

9/38

10/41

11/41

9/37

0/19a

0/26a

Skin complication, local

Bup > Fen

Bup > Fen

Swelling, non‐inflammatory

1/38

1/41

0/41

0/37

Vertigo

3/26

11/26

Vomiting

6/95

5/94

Discontinuation due to AE

6/95

1/94

6/38

3/41

5/41

3/37

Abbreviations: Bup = buprenorphine; F = fluid; Fen = fentanyl; IM = intramuscular; Mor = morphine; P = phenytoin; Pen = pentazocine; Pla = placebo; SC = subcutaneous; SD = subdermal; SL = sublingual; Sup = suppository; Tab = tablets; Til+Na = tilidin + naloxone; Tra = tramadol.
 ^aSevere.